Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BI's Mobic NDA May Test Limits Of FDA COX-2 Class Definition

Executive Summary

Boehringer Ingelheim's NDA for the nonsteroidal anti-inflammatory drug Mobic (meloxicam) may test the limits of FDA's definition of COX-2 inhibitors and their status as a separate class.

You may also be interested in...



Vioxx Strategy Aims To Switch Patients Up From OTC To Rx Market

Merck is looking to move patients out of the over-the-counter analgesic market to the prescription COX-2 inhibitor Vioxx, Merck Human Health-The Americas President David Anstice said at Merck's annual business briefing Dec. 9 in Whitehouse Station, N.J.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

PS033319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel